Aurinia Pharmaceuticals (AUPH) Gross Profit (2020 - 2026)

Aurinia Pharmaceuticals' Gross Profit history runs 7 years deep, the most recent figure standing at $71.2 million for Q1 2026.

• Quarterly Gross Profit rose 32.12% year-over-year to $71.2 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $267.7 million (up 22.67% YoY) and the FY2025 annual result came in at $250.4 million, up 21.03% from the prior year.
• Gross Profit was $71.2 million for Q1 2026 at Aurinia Pharmaceuticals, up from $68.3 million in the prior quarter.
• Across five years, Gross Profit topped out at $71.2 million in Q1 2026 and bottomed at $21.4 million in Q1 2022.
• A 5-year average of $48.1 million and a median of $48.3 million in 2024 frame the typical range for Gross Profit.
• Annual changes were most pronounced in 2022 — Gross Profit soared 2367.55% — and 2023, when it retreated 10.47%.
• Aurinia Pharmaceuticals' Gross Profit stood at $27.1 million in 2022, then soared by 46.64% to $39.7 million in 2023, then jumped by 36.81% to $54.3 million in 2024, then climbed by 25.78% to $68.3 million in 2025, then rose by 4.22% to $71.2 million in 2026.
• Business Quant data shows AUPH's Gross Profit at $71.2 million in Q1 2026, $68.3 million in Q4 2025, and $65.3 million in Q3 2025.